NeuroSense Therapeutics Ltd.
NRSN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875091
No open-market purchases or sales by NeuroSense Therapeutics Ltd. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $285.7K in total; no superinvestor holds it.
Other share classesNRSNW
13F holders, Q4 2023
Institutional positions in NeuroSense Therapeutics Ltd. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 8
- +3 vs. Q3 2023
- Shares held
- 141.6K
- −637.8K (−81.8%) vs. Q3 2023
- Total value
- $110.6K
- −$443.5K (−80.0%) vs. Q3 2023
- New holders
- 5
- 0 more added
- Sold out
- 2
- 1 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NRSN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 12 | $285.7K |
| Q1 2026 | 13 | $286.7K |
| Q4 2025 | 13 | $266.2K |
| Q3 2025 | 10 | $346.8K |
| Q2 2025 | 17 | $964.4K |
| Q1 2025 | 11 | $180.8K |
| Q4 2024 | 13 | $775.8K |
| Q3 2024 | 7 | $285.9K |
| Q2 2024 | 7 | $1.87M |
| Q1 2024 | 8 | $309.4K |
| Q4 2023 | 8 | $111.7K |
| Q3 2023 | 5 | $554.1K |
| Q2 2023 | 6 | $2.34M |
| Q1 2023 | 5 | $243.4K |
| Q4 2022 | 5 | $41.6K |
| Q3 2022 | 5 | $132.0K |
| Q2 2022 | 7 | $733.0K |
| Q1 2022 | 9 | $694.0K |
| Q4 2021 | 5 | $380.0K |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding NeuroSense Therapeutics Ltd.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Meitav Dash Investments Ltd | 95,000 | $74.6K | 0.00% | 00.0% | Unchanged |
| Scientech Research LLC | 12,584 | $10.1K | 0.01% | +12,584 | New |
| HRT Financial LP | 13,998 | $10.0K | 0.00% | +13,998 | New |
| Geode Capital Management, LLC | 11,963 | $9.39K | 0.00% | +11,963 | New |
| UBS Group AG | 5,496 | $4.31K | 0.00% | −4,169−43.1% | Reduced |
| Morgan Stanley | 1,500 | $1.18K | 0.00% | +1,500 | New |
| CWM, LLC | 1,000 | $1.00K | 0.00% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 54 | $42 | 0.00% | +54 | New |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −662,000−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −11,702−100.0% | Sold out |